Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.

Trial Details

NCT ID
NCT07341191
Phase
PHASE2
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Zanubrutinib
  • Sonrotoclax
  • CAR-T Cell Therapy
Locations (sample)
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Have histologically confirmed mantle cell lymphoma that is relapsed or refractory after at least one prior line of systemic therapy
  • Eligible for and planned to receive Health Canada approved CAR-T.
  • Have a formalin fixed paraffin embedded tumour tissue block available and must have provided informed consent for the release of the block.
  • Presence of radiologically documented disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →